Page 118 - OR-1-2

37. Duan X, Zhang L, Feng N, et al. A pancreatic cancer organoid doi: 10.1038/s41392-022-01190-w
platform identifies an inhibitor specific to mutant KRAS. Cell 49. Smyth EC, Nilsson M, Grabsch HI, Van Grieken NC, Lordick F.
Stem Cell. 2023;31:1.
Gastric cancer. Lancet. 2020;396:635-648.
doi: 10.1016/j.stem.2023.11.011
doi: 10.1016/s0140-6736(20)31288-5
38. Zhou Z, Van der Jeught K, Li Y, et al. A T cell‐engaging tumor 50. Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-
organoid platform for pancreatic cancer immunotherapy.
Adv Sci. 2023;10:2300548. derived organoids model treatment response of metastatic
gastrointestinal cancers. Science. 2018;359:920-926.
doi: 10.1002/advs.202300548
doi: 10.1126/science.aao2774
39. Grossman JE, Muthuswamy L, Huang L, et al. Organoid
sensitivity correlates with therapeutic response in patients 51. Zhao Y, Li S, Zhu L, et al. Personalized drug screening using
with pancreatic cancer. Clin Cancer Res. 2022;28:708. patient-derived organoid and its clinical relevance in gastric
cancer. Cell Rep Med. 2024;5:101627.
doi: 10.1158/1078-0432.ccr-20-4116
doi: 10.1016/j.xcrm.2024.101627
40. Cao LQ, Sun H, Xie Y, et al. Therapeutic evolution in HR+/
HER2- breast cancer: From targeted therapy to endocrine 52. Seidlitz T, Merker SR, Rothe A, et al. Human gastric cancer
therapy. Front Pharmacol. 2024;15:1340764. modelling using organoids. Gut. 2018;68:207.
doi: 10.3389/fphar.2024.1340764 doi: 10.1136/gutjnl-2017-314549
41. Wu H, Wang W, Zhang Y, et al. Establishment of patient- 53. Ukai S, Honma R, Sakamoto N, et al. Molecular biological
derived organoids for guiding personalized therapies in analysis of 5-FU-resistant gastric cancer organoids;
breast cancer patients. Int J Cancer. 2024;155:324-338. KHDRBS3 contributes to the attainment of features of cancer
stem cell. Oncogene. 2020;39:7265-7278.
doi: 10.1002/ijc.34931
doi: 10.1038/s41388-020-01492-9
42. Mazzucchelli S, Signati L, Messa L, et al. Breast cancer
patient-derived organoids for the investigation of patient- 54. Harada K, Sakamoto N, Ukai S, et al. Establishment of
specific tumour evolution. Cancer Cell Int. 2024;24:220. oxaliplatin-resistant gastric cancer organoids: Importance of
myoferlin in the acquisition of oxaliplatin resistance. Gastric
doi: 10.1186/s12935-024-03375-5 Cancer. 2021;24:1264-1277.
43. Dijkstra KK, Monkhorst K, Schipper LJ, et al. Challenges in doi: 10.1007/s10120-021-01206-4
establishing pure lung cancer organoids limit their utility for
personalized medicine. Cell Rep. 2020;31:107588. 55. Yan HHN, Siu HC, Law S, et al. A comprehensive human
gastric cancer organoid biobank captures tumor subtype
doi: 10.1016/j.celrep.2020.107588 heterogeneity and enables therapeutic screening. Cell Stem
44. Dost AFM, Moye AL, Vedaie M, et al. Organoids model Cell. 2018;23:882-897.e11.
transcriptional hallmarks of oncogenic KRAS activation doi: 10.1016/j.stem.2018.09.016
in lung epithelial progenitor cells. Cell Stem Cell. 2020;27:
663-678.e8. 56. Schmäche T, Fohgrub J, Klimova A, et al. Stratifying
esophago-gastric cancer treatment using a patient-derived
doi: 10.1016/j.stem.2020.07.022 organoid-based threshold. Mol Cancer. 2024;23:10.
45. Kim SY, Kim SM, Lim S, et al. Modeling clinical responses to doi: 10.1186/S12943-023-01919-3
targeted therapies by patient-derived organoids of advanced
lung adenocarcinoma. Clin Cancer Res. 2021;27:4397-4409. 57. James ND, Tannock I, N’Dow J, et al. The lancet commission
on prostate cancer: Planning for the surge in cases. Lancet.
doi: 10.1158/1078-0432.CCR-20-5026
2024;403:1683-1722.
46. Shi R, Radulovich N, Ng C, et al. Organoid cultures as doi: 10.1016/s0140-6736(24)00651-2
preclinical models of non-small cell lung cancer. Clin Cancer
Res. 2020;26:1162-1174. 58. Gao D, Vela V, Sboner V, et al. Organoid cultures derived
from patients with advanced prostate cancer. Cell. 2014;159:
doi: 10.1158/1078-0432.ccr-19-1376
176-187.
47. Wang HM, Zhang CY, Peng KC, et al. Using patient-derived doi: 10.1016/j.cell.2014.08.016
organoids to predict locally advanced or metastatic lung
cancer tumor response: A real-world study. Cell Rep Med. 59. Servant R, Garioni M, Vlajnic T, et al. Prostate cancer patient‐
2023;4:100911. derived organoids: Detailed outcome from a prospective
cohort of 81 clinical specimens. J Pathol. 2021;254:543.
doi: 10.1016/j.xcrm.2022.100911
doi: 10.1002/path.5698
48. Lei ZN, Teng QX, Tian Q, et al. Signaling pathways and
therapeutic interventions in gastric cancer. Signal Transduct 60. Heninger E, Kosoff D, Rodems TS, et al. Live cell molecular
Target Ther. 2022;7(1):358. analysis of primary prostate cancer organoids identifies

Volume 1 Issue 2 (2025) 12 doi: 10.36922/OR025050008